Because the immunogenicity of EGFR-mutant NSCLC is weak, while CD8 + T-cell infiltration decreases, antitumor effects weaken, Treg cells increase, and CD37 is overexpressed; all of the above findings indicate that EGFR-mutant NSCLC has an immunosuppressive tumor microenviroment (TME), which renders these NSCLC patients insensitive to immunotherapy [7, 8]. Here, EGFR is linked to neoplasm.